Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 17;5(9):e02343.
doi: 10.1016/j.heliyon.2019.e02343. eCollection 2019 Sep.

A cost-utility analysis of Amisulpride and Paliperidone in the treatment of Schizophrenia

Ali Abdall-Razak  1 , Alex Macaulay  1 , Jakov Tiefenbach  2 , Karen Borges  3 , Sina Mathema  3 , Sameer Zuberi  1
Affiliations

A cost-utility analysis of Amisulpride and Paliperidone in the treatment of Schizophrenia

Ali Abdall-Razak et al. Heliyon. .

Abstract

Background: Schizophrenia is a severe, long-term neurodevelopmental disorder that results in increased morbidity and mortality. Amisulpride and Paliperidone are two antipsychotics used to treat schizophrenia in the UK. This evaluation compares the cost-utility of each drug; no similar research has been conducted in the UK.

Methods: A cost utility analysis was performed looking at the benefits in terms of Quality Adjusted Life Years within one year of the treatment, and the costs in pound sterling, discounted to the 2016/2017 value. This evaluation was from the perspective of the National Health Service, the biggest provider of health within the United Kingdom.

Outcomes: The cost utility analysis found an incremental cost effectiveness ratio of £10,941 per added Quality Adjusted Life Year for using Paliperidone, instead of the more widely used Amisulpride.

Interpretation: This is below the NICE threshold of £20-30,000 per QALY. Hence, it is within reason to suggest shifting diagnostic practices to Paliperidone.

Keywords: Amisulpride; Cost-utility; Economics; Paliperidone; Psychiatry; Schizophrenia.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Decision Tree: shows the associated costs (C), probabilities (P) and utilities (U) for side effects of the treatments Amisulpride and Paliperidone. See Appendices 1, 2, 3, 4, 5, 6 for calculations.
Fig. 2
Fig. 2
Cost Effectiveness Plane: showing the position of Paliperidone against the thresholds held by the NHS .
See this image and copyright information in PMC

References

    1. BMJ Best Practice . 2017. Schizophrenia.http://bestpractice.bmj.com/topics/en-gb/406/pdf/406.pdf Available from:
    1. Mitchell A.J., Malone D. Physical health and schizophrenia. Curr. Opin. Psychiatr. 2006 Jul;19(4):432–437. - PubMed
    1. NHS Choices. Schizophrenia. Available from: https://www.nhs.uk/conditions/schizophrenia/causes/. (Accessed 26 February 2018).
    1. Jones S., Fernyhough C. A new look at the neural diathesis–stress model of schizophrenia: the primacy of social-evaluative and uncontrollable situations. Schizophr. Bull. 2007 Sep;33(5):1171–1177. - PMC - PubMed
    1. American Psychiatric Association . fifth ed. October 2017. Supplement to Diagnostic and Statistical Manual of Mental Disorders.https://psychiatryonline.org/pb-assets/dsm/update/DSM5Update_October2017... Available from:

LinkOut - more resources